Andrew R. Pettitt

Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

Richard R. Furman, Jeff P. Sharman, Steven Coutré et al. · New England Journal of Medicine · 2014 · 1.7K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia

Maria Chiara Di Bernardo, Dalemari Crowther-Swanepoel, Peter Broderick et al. · Nature Genetics · 2008 · 360 citations

Life Sciences, Genetics, Molecular Genetics +12

Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial

Peter Hillmen, Tadeusz Robak, Ann Janssens et al. · The Lancet · 2015 · 339 citations

Life Sciences, Oncology, Pharmacology +17

Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study

Peter Hillmen, Andy C. Rawstron, Kristian Brock et al. · Journal of Clinical Oncology · 2019 · 271 citations · Full text

Medicine, Immunology, Pharmacotherapy +14

DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma

Ian W. Flinn, Carole B. Miller, Kirit M. Ardeshna et al. · Journal of Clinical Oncology · 2019 · 264 citations · Full text

Medicine, Oncology, Pharmacotherapy +13